The 6 references in paper , статья Редакционная (2019) “Резолюция экспертного совета по вопросу о роли цетуксимаба в лечении пациентов с плоскоклеточным раком головы и шеи // The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council” / spz:neicon:ogsh:y:2018:i:4:p:71-73

1
Российское общество специалистов по опухолям головы и шеи, Ассоциация онкологов России. Рак гортани. Клинические рекомендации. Доступно по: http://oncology-association.ru/files/clinicalguidelines_adults/rak_gortani. pdf [Russian Society of Head and Neck Tumors Specialists, Association of Russian Oncologists. Larynx cancer. Clinical guidelines. Available at: http://oncologyassociation.ru/files/clinical-guidelines_ adults/rak_gortani.pdf (In Russ.)].
(check this in PDF content)
2
Bonner J. A., Harari P. M., Giralt J. et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78. DOI: 10.1056/ NEJMoa053422. PMID: 16467544.
(check this in PDF content)
3
Bonner J. A., Mesia R., Giralt J. et al. p16, HPV, and cetuximab: what is the evidence? Oncologist 2017;22(7):811–22. DOI: 10.1634/theoncologist.2016-0433. PMID: 28526718.
(check this in PDF content)
4
Vermorken J. B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11): 1116–27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101.
(check this in PDF content)
5
Burtness B., Harrington K. J., Greil R. et al. KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Available at: https://www. esmo.org/Press-Office/Press-Releases/ KEYNOTE048-head-neck-cancerimmunotherapy-Burtness.
(check this in PDF content)
6
Saleh K., Daste A., Martin N. et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. J Clin Oncol
(check this in PDF content)